Educational only — not medical advice. If you’re in crisis or thinking about suicide: call or text 988 (U.S.) or your local emergency number. Support resources. Under construction and review—see the updates log.

lisdexamfetamine

Adjunctive therapy

Brand: VYVANSE

Published 2026-02-13 · Last reviewed 2026-02-20 · 4 references

Content sourced from FDA labeling (DailyMed) and peer-reviewed literature.

Print sheet Review evidence

At a glance

Class: Adjunctive therapy·Typical dose: Usually once daily in the morning; afternoon/evening dosing is typically avoided due to insomnia risk.·Half-life: Single-dose mean 11 h·LAI available: No

Class: Adjunctive therapy
Typical dose: Usually once daily in the morning; afternoon/evening dosing is typically avoided due to insomnia risk.
Half-life: Single-dose mean 11 h
LAI available: No

Quick answers

What is lisdexamfetamine?: Lisdexamfetamine (brand Vyvanse) is a Schedule II stimulant used for ADHD. It is a prodrug converted to dextroamphetamine, which tends to produce a smoother onset and longer duration for many patients compared with some immediate-release amphetamine products.
What is VYVANSE?: VYVANSE is a brand name for lisdexamfetamine.
What is VYVANSE (lisdexamfetamine) used for?: Label indications include: Attention-deficit/hyperactivity disorder (ADHD); binge eating disorder in adults (product-dependent).
What drug class is VYVANSE (lisdexamfetamine)?: CNS Stimulant.
What is the mechanism of action of VYVANSE (lisdexamfetamine)?: Prodrug stimulant converted to dextroamphetamine; increases dopamine and norepinephrine signaling.
What strengths does VYVANSE (lisdexamfetamine) come in?: Oral capsules and chewable tablets (product-dependent).

General information

Lisdexamfetamine is a prodrug stimulant converted to dextroamphetamine. It is used as a first-line medication option for ADHD and is also approved for binge eating disorder in adults.

The prodrug design often yields a smoother onset and longer duration for many patients, but it remains a Schedule II controlled substance with meaningful misuse/diversion potential.

In patients with serious mental illness or vulnerability to mania or psychosis, stimulants can worsen insomnia, anxiety, irritability, mania, or psychosis. Diagnosis confirmation and stabilization of the primary illness are often prioritized before stimulant trials, with cautious titration and close follow-up.

The lisdexamfetamine compare view, the evidence feed, and the print page support side-by-side review and patient-friendly counseling on safe use and monitoring.

U.S. approvals

Attention-deficit/hyperactivity disorder (ADHD)
Binge eating disorder (adults)

Formulations & strengths

Oral capsules and chewable tablets (product-dependent).

Generic availability

Generic availability varies by market and year; verify current formulary status.

The most common failures are late-day dosing that disrupts sleep, dose escalation despite appetite loss and anxiety, and under-recognition of bipolar/psychosis vulnerability or substance use. Success depends on matching the regimen to daytime impairment and monitoring for both cardiovascular effects and psychiatric activation.

View labelExact

Mechanism of action

Refer to the Glossary entry on Neurotransmitters for background on receptor systems involved in serious mental illness.

Converted to dextroamphetamine, which increases dopamine and norepinephrine signaling via release and reuptake inhibition.

Clinical benefits can be rapid; response is often evaluated using functional targets (task completion, fewer errors, safer driving) rather than subjective energy.

Activating effects can worsen insomnia and anxiety when dosing is late or titration is too aggressive.

Increases dopamine and norepinephrine via release and reuptake inhibition (active metabolite).
Central sympathomimetic effects drive both benefit and adverse reactions.

Metabolism & pharmacokinetics

Prodrug converted by enzymatic hydrolysis (primarily in blood) to active dextroamphetamine; conversion is not CYP-mediated.
Elimination of active amphetamine is influenced by urinary pH; acidifying agents can increase clearance while alkalinizing agents can prolong effects.
Clinical duration is often long enough for once-daily dosing; late-day insomnia is often used as a practical marker of excessive duration.

Dosing & administration

Usually once daily in the morning; afternoon/evening dosing is typically avoided due to insomnia risk.
Typical adult starting dose is 30 mg once daily, with titration in 10–20 mg steps (often weekly) based on response and tolerability.
Typical effective range is 30–70 mg/day; maximum recommended dose is 70 mg/day (label).
If response is minimal at reasonable doses, ADHD diagnosis, sleep disorders, anxiety/depression, and substance use are often reassessed before continued dose escalation.

Monitoring & labs

Baseline and periodic blood pressure and heart rate (more often during titration).
Appetite and weight/BMI are tracked; nutrition and meal timing are revisited if weight loss occurs.
Sleep onset and duration are monitored; timing adjustments are often tried before adding sedatives.
Anxiety, agitation, mood elevation, or hallucinations are monitored; if concerning symptoms emerge, discontinuation and reassessment are common.
Misuse/diversion risk is reviewed and safe storage counseling is documented.

Sources: DailyMed label; guideline statements; network meta-analysis context.

Adverse effects

FDA boxed warnings

Boxed warning: CNS stimulants have a high potential for abuse and dependence; misuse risk assessment and monitoring for diversion or escalating use are standard parts of safe prescribing.

Common side effects (≥10%)

Appetite suppression / weight loss: Common; weight/BMI are tracked, and meal timing and nutrition strategies are often discussed.
Insomnia: Often reflects late dosing or excessive duration; earlier dosing and reassessment are common first steps.
Increased heart rate / blood pressure: Vitals are monitored during titration; cardiovascular disease warrants added caution.
Anxiety / irritability: Can emerge with rapid titration; slower titration and reassessment of comorbid anxiety/bipolar risk are common adjustments.
Dry mouth / GI upset / headache: Often improves with time; slower titration may help if limiting.

Other notable effects

Psychiatric symptoms can include agitation, mood elevation, or hallucinations; discontinuation and reassessment are typical if mania or psychosis emerges.
Misuse/diversion risk remains clinically important despite prodrug design; safe storage counseling and clear refill policies are commonly used.

Interactions

Contraindicated with MAO inhibitors; a washout period is typically used.
Urinary acidifying or alkalinizing agents can meaningfully alter exposure and duration; supplements and OTC products are reviewed when effects change.
Additive sympathomimetic effects with decongestants or other stimulants can worsen anxiety and cardiovascular effects.

Other useful information

Titration is often anchored to function and revisited after each dose adjustment; “dose chasing” when sleep is deteriorating is generally avoided.
Sleep disorders are screened and treated; insomnia can mimic ADHD and stimulants can worsen delayed sleep phase if dosing is late.
In bipolar spectrum illness or psychosis vulnerability, stabilization of the primary illness is typically prioritized, with close monitoring for activation.
Diversion prevention counseling often includes locked storage, not sharing, and clear refill policies.

References

Related hubs:SMI toolkit·Support resources